Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 33, Issue 3, Pages 259-275
Publisher
Elsevier BV
Online
2021-12-16
DOI
10.1016/j.annonc.2021.12.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
- (2021) Carlota Gudiol et al. Lancet Haematology
- Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy
- (2021) David Beauvais et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells
- (2021) David C Bishop et al. BLOOD
- The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity
- (2021) Ahmed Aqel et al. Current Research in Translational Medicine
- Graft‐ versus ‐host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation
- (2021) Maria Gabelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Effective anti-BCMA retreatment in multiple myeloma
- (2021) Nicolas Gazeau et al. Blood Advances
- SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observations
- (2021) Muhammad Abbas Abid et al. HEMATOLOGICAL ONCOLOGY
- Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
- (2021) Paolo F. Caimi et al. Frontiers in Immunology
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas
- (2020) Jeremy S. Abramson et al. BLOOD
- Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
- (2020) Jennifer M. Logue et al. HAEMATOLOGICA
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients
- (2020) Daphna Hutt et al. TRANSFUSION AND APHERESIS SCIENCE
- Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
- (2020) Felix Korell et al. Cells
- Use of Commercial anti‐CD19 CAR T Cell Therapy for Patients with Relapsed/Refractory Aggressive B Cell Lymphoma in a European center
- (2020) Pierre Sesques et al. AMERICAN JOURNAL OF HEMATOLOGY
- How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies
- (2020) Joshua A. Hill et al. BLOOD
- G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
- (2020) Eugenio Galli et al. BONE MARROW TRANSPLANTATION
- Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma
- (2020) David Beauvais et al. CURRENT OPINION IN ONCOLOGY
- Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
- (2020) Paolo Strati et al. HAEMATOLOGICA
- Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
- (2020) Carlos A. Ramos et al. JOURNAL OF CLINICAL ONCOLOGY
- CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
- (2020) Yongxian Hu et al. Current Research in Translational Medicine
- Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome
- (2020) Nirav N. Shah et al. Blood Advances
- Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
- (2020) Tania Jain et al. Blood Advances
- Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis
- (2020) Avirup Guha et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients
- (2020) Andrea Jarisch et al. JOURNAL OF CLINICAL APHERESIS
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies
- (2020) Valentín Ortíz-Maldonado et al. MOLECULAR THERAPY
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- (2020) Michael Wang et al. Journal for ImmunoTherapy of Cancer
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- (2020) Marcela V Maus et al. Journal for ImmunoTherapy of Cancer
- Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome
- (2019) Olha Halyabar et al. Pediatric Rheumatology
- Neurological toxicities associated with chimeric antigen receptor T-cell therapy
- (2019) Daniel B Rubin et al. BRAIN
- Early and late hematologic toxicity following CD19 CAR-T cells
- (2019) Shalev Fried et al. BONE MARROW TRANSPLANTATION
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells
- (2019) Philipp Karschnia et al. BLOOD
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma
- (2019) Matthew J. Frigault et al. BLOOD
- Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
- (2019) Austin J. Sim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
- (2019) Ana Cordeiro et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Preservation of cell-based immunotherapies for clinical trials
- (2019) RUI LI et al. CYTOTHERAPY
- An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT
- (2019) P.J. Hayden et al. Current Research in Translational Medicine
- Invasive Mold Infections After Chimeric Antigen Receptor–Modified T-cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis
- (2019) Ghady Haidar et al. CLINICAL INFECTIOUS DISEASES
- Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- (2019) Ibrahim Yakoub-Agha et al. HAEMATOLOGICA
- Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
- (2019) Raza M. Alvi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
- (2019) George R. Nahas et al. LEUKEMIA & LYMPHOMA
- Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience
- (2018) Danielle S. Burstein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
- (2018) Ibrahim Yakoub-Agha Current Research in Translational Medicine
- Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations
- (2018) Christian Chabannon et al. Current Research in Translational Medicine
- Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
- (2018) Jordan Gauthier et al. Current Research in Translational Medicine
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Clinical Utilization of Chimeric Antigen Receptors T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation
- (2018) Ankit J. Kansagra et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- (2018) Noelle Frey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy
- (2018) Kevin A. Hay BRITISH JOURNAL OF HAEMATOLOGY
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous lymphapheresis for the production of chimeric antigen receptor T cells
- (2017) Elizabeth S. Allen et al. TRANSFUSION
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives
- (2017) J. Gauthier et al. Current Research in Translational Medicine
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- A safe therapeutic apheresis protocol in paediatric patients weighing 11 to 25 kg
- (2014) R. W. Maitta et al. VOX SANGUINIS
- Cornell Assessment of Pediatric Delirium
- (2013) Chani Traube et al. CRITICAL CARE MEDICINE
- Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation
- (2011) Navneet S. Majhail et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now